Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Analyst Upgrades Alkermes' Shares

August 31, 2011 7:22 am | News | Comments

A Caris & Co. analyst upgraded the stock of drug developer Alkermes Inc., pointing to the company's pending acquisition of a drug technology business.

TOPICS:

Rough Start for Benlysta

August 31, 2011 7:14 am | News | Comments

A new lupus treatment developed by Human Genome Sciences Inc. is receiving a lukewarm reception from doctors so far, with demand for the drug shaping up to be much softer than expected, according to a Citi analyst.

TOPICS:

NIH Database to Speed Research Up for Brain Injuries

August 30, 2011 12:32 pm | News | Comments

The National Institutes of Health, in partnership with the Department of Defense, is building a central database on traumatic brain injuries.

TOPICS:
Advertisement

Kuros Completes Patient Recruitment for KUR-023

August 30, 2011 12:28 pm | News | Comments

Kuros Biosurgery completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

TOPICS:

Inspiration, Ipsen Partner on Hemophilia Launch

August 30, 2011 12:24 pm | News | Comments

Ipsen and Inspiration Biopharmaceuticals Inc. entered into a strategic partnership agreement, to create a European hemophilia commercial organization, to launch Inspiration’s hemophilia product portfolio in Europe.

TOPICS:

Trying to Starve Breast Cancer Cells

August 30, 2011 12:20 pm | News | Comments

The most common breast cancer uses the most efficient, powerful food delivery system known in human cells and blocking that system kills it, researchers report.

TOPICS:

Scripps Research and Stanford Scientists Find Drug Candidates

August 30, 2011 12:15 pm | News | Comments

Collaborating researchers at Stanford University and The Scripps Research Institute have identified chemical compounds that show promise as potential therapeutics for a set of medical conditions caused by the abnormal clumping together of a protein known as transthyretin (TTR).

TOPICS:

Identified Gene Mutation May Underlie Other Cancer Types

August 30, 2011 12:11 pm | News | Comments

Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer -- mesothelioma, and melanoma of the eye.

TOPICS:
Advertisement

Childhood Cancers Take a Beating from Virus

August 30, 2011 12:06 pm | News | Comments

Yale University researchers are looking to fight a form of cancer primarily found in children and young adults with a virus from the same family as the rabies virus.

TOPICS:

Toxicity Assay

August 30, 2011 8:16 am | Product Releases | Comments

Promega Corporation announced the launch of ONE-Glo + Tox Assay, for improved analysis of reporter gene expression in the context of cell health.

TOPICS:

mRNA-based Cell Reprogramming

August 30, 2011 8:05 am | Product Releases | Comments

Highly modified, synthetic 5-prime capped mRNA products for reprogramming of human cells for reprogramming cell fate are now available from AMSBIO.

TOPICS:

EMD Millipore Acquiring Amnis

August 30, 2011 7:50 am | News | Comments

EMD Millipore, the Life Science division of Merck KGaA, announced it has agreed to acquire Seattle-based Amnis Corporation. Amnis designs, manufactures and markets high speed cell imaging instrumentation.

TOPICS:

Generic Extina Approved by Regulators

August 30, 2011 7:44 am | News | Comments

The drugmaker Perrigo Co. said the Food and Drug Administration has approved its generic version of the skin disease treatment Extina foam. Extina foam has annual sales of $10 million.

TOPICS:

FDA Turns Down Migraine Patch

August 30, 2011 7:29 am | News | Comments

NuPathe Inc. said the Food and Drug Administration did not approve its Zelrix migraine patch. The FDA requested more information on the chemistry and manufacturing of the treatment, as well as citing safety concerns.

TOPICS:

Copaxone Lawsuit Moving Forward

August 30, 2011 7:22 am | News | Comments

Teva Pharmaceutical Industries Ltd. said that its patent infringement lawsuit against companies that are trying to market a generic version of its multiple sclerosis drug Copaxone will go to trial.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading